Open an account

PepGen

PEPG · NASDAQ

$2.87+$0.17 (+6.30%)TodayMarket closed ·
Prev close $2.70

About PEPG

PepGen Inc. develops oligonucleotide therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2022-05-06. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. The company is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Employees
56
Headquarters
Cambridge, Massachusetts
Listed
May 6, 2022
Sector
Health Care
Industry
Biotechnology
Website
pepgen.com

PEPG key statistics

Market cap
198.77M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
894.17K
Volume
2.77M
Open price
$2.66
High today
$2.94
Low today
$2.62
52 Week high
$7.80
52 Week low
$1.31

PepGen (PEPG) at a glance

As of Oct 20, 2026, PepGen (PEPG) shares are priced at $2.87, giving the company a market cap of 198.77M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.62 and $2.94. The current price is 9.5% above the day's low and 2.4% below its high.

Volume so far is 2.77M shares, above the average of 894.17K shares a day.

Over the past year PepGen has ranged from $1.31 to $7.80, and now sits 24% of the way up that range.

PepGen met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.26 per share against an estimate of -$0.2958.

The average analyst price target is $10.39, 262.1% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 10 analystsAvg $10.39
Low
$2.53
Now
$2.87
High
$21.00

PEPG earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 18.5% on average.

  1. Q3 FY24: reported -$0.66 per share against an estimate of -$0.8854
  2. Q4 FY24: reported -$0.682 per share against an estimate of -$0.8288
  3. Q1 FY25: reported -$0.92 per share against an estimate of -$0.7344
  4. Q2 FY25: reported -$0.70 per share against an estimate of -$0.8441
  5. Q3 FY25: reported -$0.52 per share against an estimate of -$0.5763
  6. Q4 FY25: reported -$0.27 per share against an estimate of -$0.3818
  7. Q1 FY26: reported -$0.26 per share against an estimate of -$0.3182
  8. Q2 FY26: reported -$0.26 per share against an estimate of -$0.2958

PEPG news

  • Press releaseBusiness Wire

    PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

  • Press releaseBusiness Wire

    PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

  • Press releaseBusiness Wire

    PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

  • Press releaseBusiness Wire

    PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

Similar companies

Companies in the same industry as PepGen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.